Chronic kidney disease

Where the papers sit

10 papers from the last 6 months study chronic kidney disease directly · updated from PubMed 1 Nov 2026

• CKD Risk Prediction

  Risk assessment is moving toward combining eGFR with inflammatory and hematologic markers rather than relying on kidney function alone. Platelet-to-lymphocyte ratio and hemoglobin-albumin-lymphocyte scores recur in patient and animal studies. Regression models target CKD after nephrectomy and after childhood ifosfamide exposure. Single-cell and spatial damage scores add a trajectory-based view, but external validation and clinical utility remain open.

  5 papers · 50%

• CKD Care and Comorbidity

  CKD management is being framed around metabolic, nutritional and primary-care comorbidity rather than kidney measures alone. Diabetes, obesity, anemia and hypertriglyceridemia recur across eGFR and albuminuria categories. Body-composition phenotypes are being linked to anemia and metabolic abnormalities, while prescribing data expose an SGLT2i treatment gap. The direction is toward integrated risk recognition and implementation, with real-world uptake still lagging evidence.

  3 papers · 30%

• Diabetic Kidney Disease Trends

  Diabetic kidney disease is increasingly tracked as a changing population burden across type 1 and type 2 diabetes. Long-term estimates from China, the USA and the UK emphasize geographic differences in prevalence and disability-adjusted life years. Atherogenic index measures add a metabolic-risk perspective for type 2 diabetes-associated kidney disease. The shared priority is earlier, more stratified prevention, although these studies remain observational.

  2 papers · 20%